Sinclair Pharma and Orapharma mutually agree to terminate US distribution agreement for Decapinol
The effect of this termination is that Sinclair is immediately free to license and reposition the product for a much larger target market, including the over-the-counter (OTC) market in the US. The agreement with Orapharma effectively meant the product would not reach the OTC market for some years. Sinclair is in discussions about the opportunities and is confident that the long term benefit to shareholders can outweigh any short-term loss of potential milestone income from Orapharma.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.